

ValiRx PLC
("ValiRx" or the "Company")

Commercial Update

London, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, is pleased to provide the following update on the commercial activity of its wholly owned subsidiary Inaphaea BioLabs ("Inaphaea").

Inaphaea is pleased to announce the execution of an evaluation and commercial use agreement ("Evaluation and Commercial Agreement") with UK based Dominion Biotech Ltd ("Dominion") to co-market services based on a client ownership model, where each company operates independently whilst marketing and delivering services using their combined PDC biobanks. The Evaluation and Commercial Agreement provides mutual access to Inaphaea's range of 66 cancer types alongside Dominion's collected tumour samples with comprehensive genetic profiling (NGS based mutation profiling and RNA-Seq expression analysis). Access to PDCs and services by each company will be agreed on a case-by-case basis subject to a minimum fee. The Evaluation and Commercial Agreement is for a period of 12 months initially and may be extended in writing by mutual agreement.

An evaluation use agreement ("Evaluation Agreement") has also been executed with UK based Cellomatics Biosciences Ltd ("Cellomatics"). The Evaluation Agreement initially focusses on in house evaluation of Inaphaea's Colorectal Cancer PDCs by Cellomatics which, if successful, will be offered for commercial services by Cellomatics and Inaphaea on terms to be agreed. Both companies have also agreed to co-market their respective services. The Evaluation Agreement is for a period of 12 months initially and may be extended in writing by mutual agreement.

Mark Eccleston, CEO of ValiRx commented "We're pleased to announce two further deals for Inaphaea's PDC biobank. Both deals demonstrate the commercial potential and interest in the biobank and support our approach to cross marketing to achieve better market awareness and penetration of this resource. The Dominion deal brings a new angle whereby we can access additional, prospectively collected models for clients whilst dominion benefits from our established biobank. Cellomatics are a Nottingham based Contract Research Organisation with an established client base and complementary pre-clinical testing capabilities."

Anthony Holmes, CEO of Dominion commented "We're excited to partner with Inaphaea to expand access to patient-derived cancer models for drug discovery and development. This collaboration combines Dominion's expertise in collecting and characterizing fresh tumour samples with Inaphaea's established biobank of diverse cancer types, creating a powerful resource for pharmaceutical companies seeking to improve clinical trial success rates. By joining forces under this innovative client ownership model, we can offer clients an even more comprehensive service while maintaining our independent operations. We look forward to working with the Inaphaea team to accelerate the development of more effective cancer therapies."

Shailendra Singh, CEO of Cellomatics commented "We are excited to announce the execution of an Evaluation Agreement with Inaphaea BioLabs. This collaboration marks an important step forward in expanding our oncology service offerings, starting with the in-house evaluation of Inaphaea's Colorectal Cancer PDCs. If successful, we look forward to jointly offering these cutting-edge models as part of our commercial service portfolio. This partnership reflects Cellomatics' commitment to innovation, collaboration, and delivering meaningful value to our clients in the oncology space."

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company take responsibility for this announcement.

***** ENDS *****

Engage with the ValiRx management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor hub here: <https://valirx.com/s/cc8ef3>

For more information, please contact:

Investor questions on this announcement We encourage all investors to share questions on this announcement via our investor hub	https://valirx.com/link/lyapKP
ValiRx plc Dr Mark Eccleston, CEO	Tel: +44 115 784 0025 www.valirx.com Mark.Eccleston@valirx.com
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Ludovico Lazzaretti	Tel: +44 (0) 20 7213 0880

Shard Capital Partners LLP (Sole Broker) Damon Heath	Tel: +44 (0) 20 7186 9000
V Formation (Public Relations) Lucy Wharton - Senior PR Executive Sue Carr - Director	+44 (0) 115 787 0206 www.vformation.biz lucy@vformation.biz sue@vformation.biz

Subscribe to our news alert service: <https://valirx.com/s/f298d1>

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

UPDFZGZDLLGGKZM